Merus NV
NASDAQ:MRUS

Watchlist Manager
Merus NV Logo
Merus NV
NASDAQ:MRUS
Watchlist
Price: 42.46 USD 1.46%
Market Cap: 2.9B USD
Have any thoughts about
Merus NV?
Write Note

P/S
Price to Sales

80.9
Current
26.3
Median
7.6
Industry
Higher than median
Higher than industry value

Price to Sales (P/S) ratio is a valuation multiple that compares a company’s market capitalization to its revenues. It is an indicator of the value that financial markets have placed on each dollar of a company’s sales.

P/S
80.9
=
Market Cap
2.9B USD
/
Revenue
35.9m USD
All Countries
Close
Revenue Growth P/S to Growth
NL
Merus NV
NASDAQ:MRUS
Average P/S: 3 457 247.3
80.9
93%
0.9
FR
Pharnext SCA
OTC:PNEXF
38 027 714.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.6
20%
0.3
US
Amgen Inc
NASDAQ:AMGN
4.4
26%
0.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.1
10%
0.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.5
34%
0.3
US
E
Epizyme Inc
F:EPE
1 852.6
N/A N/A
AU
CSL Ltd
ASX:CSL
5.7
23%
0.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
23%
0.2
US
S
Seagen Inc
F:SGT
17.8
118%
0.2
NL
argenx SE
XBRU:ARGX
19.3
220%
0.1

P/S Forward Multiples

Forward P/S multiple is a version of the P/S ratio that uses forecasted revenue for the P/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/S
76.1
2-Years Forward
P/S
48.4
3-Years Forward
P/S
33.8

See Also

Discover More